Functional rescue of a defective angiotensin II AT1 receptor mutant by the Mas protooncogene

Regulatory Peptides

Volumn 141, Issue 1-3, 2007, Pages 159-167

  Santos, Edson L ^a   Reis, Rosana I ^b   Silva, Ronaldo G ^a   Shimuta, Suma I ^a   Pecher, Christiane ^c   Bascands, Jean Loup ^c   Schanstra, Joost P ^c   Oliveira, Laerte ^a   Bader, Michael ^d   Paiva, Antonio C M ^a   Costa Neto, Claudio M ^b   Pesquero, João B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSERM   (France)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Angiotensin II; AT1 receptor; Dimerization; G protein coupled receptor; Mas protooncogene

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; HETERODIMER; INOSITOL PHOSPHATE;

ACIDIFICATION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL ASSAY; CELL MEMBRANE; CELL MUTANT; CELL STRAIN COS7; CELLULAR DISTRIBUTION; CHO CELL; CONTROLLED STUDY; DIMERIZATION; GENETIC TRANSFECTION; HORMONE ACTION; IMMUNOFLUORESCENCE; NONHUMAN; ONCOGENE MAS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTO ONCOGENE; RECEPTOR BINDING;

AMINO ACID SEQUENCE; ANGIOTENSIN II; ANIMALS; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; FLUORESCEINS; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; FLUORESCENT DYES; INDOLES; INHIBITORY CONCENTRATION 50; INOSITOL PHOSPHATES; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; TRANSFECTION;

EID: 33947602815     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.12.030     Document Type: Article

References (59)

1. Hunyady L., Catt K.J., Clark A.J., and Gaborik Z. Mechanisms and functions of AT(1) angiotensin receptor internalization. Regul Pept 91 (2000) 29-44
2. De Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International union of pharmacology, XXIII, The angiotensin II receptors. Pharmacol Rev 52 (2000) 415-472
3. Hjorth S.A., Schambye H.T., Greenlee W.J., and Schwartz T.W. Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J Biol Chem 269 (1994) 30953-30959
4. Costa-Neto C.M., Miyakawa A.A., Oliveira L., Hjorth S.A., Schwartz T.W., and Paiva A.C. Mutational analysis of the interaction of the N- and C-terminal ends of angiotensin II with the rat AT(1A) receptor. Br J Pharmacol 130 (2000) 1263-1268
5. Santos E.L., Pesquero J.B., Oliveira L., Paiva A.C.M., and Costa-Neto C.M. Mutagenesis of the AT1 receptor reveals different binding modes of angiotensin II and [Sar1]-angiotensin II. Regul Pept 119 (2004) 183-188
6. Oliveira L., Paiva A.C.M., Sander C., and Vriend G. A common step for signal transduction in G protein-coupled receptors. Trends Pharmacol Sci 15 (1994) 170-172
7. Noda K., Saad Y., and Karnik S.S. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem 270 (1995) 28511-28514
8. Han H.M.C.B., Shimuta S.I., Kanashiro C.A., Oliveira L., Han S.W., and Paiva A.C.M. Residues Val254, His256, and Phe259 of the angiotensin II AT1 receptor are not involved in ligand binding but participate in signal transduction. Mol Endocrinol 12 (1998) 810-814
9. Ohyama K., Yamano Y., Sano T., Nakagomi Y., Wada M., and Inagami T. Role of the conserved DRY motif on G protein activation of rat angiotensin II receptor type 1A. Biochem Biophys Res Commun 292 (2002) 362-367
10. Wang C., Jayadev S., and Escobedo J.A. Identification of a domain in the angiotensin II type 1 receptor determining Gq coupling by the use receptor chimera. J Biol Chem 270 (1995) 16677-16682
11. Hunyady L., Bor M., Baukal A.J., Balla T., and Catt K.J. A conserved NPLFY sequence contributes to agonist binding and signal transduction but not an internalization signal for the type 1 angiotensin II receptor. J Biol Chem 270 (1995) 16602-16609
12. S, Perlman, H.T. Schambye, R.A. Rivero, W.J. Greenlee, S.A. Hjorth, and T.W. Schwartz, Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor, J Biol Chem 270, pp. 1493-1496.
13. Costa-Neto C.M., Miyakawa A.A., Pesquero J.B., Oliveira L., Hjorth S.A., Schwartz T.W., and Paiva A.C. Interaction of a non-peptide agonist with angiotensin II AT1 receptor mutants. Can J Physiol Pharmacol 80 (2002) 413-417
14. Leung P.S. The peptide hormone angiotensin II: its new functions in tissues and organs. Curr Protein Pept Sci 54 (2004) 267-273
15. Haulica I., Bild W., and Serban D.N. Angiotensin peptides and their pleiotropic actions. J Renin Angiotensin Aldosterone Syst 6 (2005) 121-131
16. Ferreira A.J., and Santos R.A. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 38 (2005) 499-507
17. Santos R.A., Simoes-Silva A.C., Maric C., Silva D.M., Machado R.P., Buhr I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.P., Speth R., and Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100 (2003) 8258-8263
18. Pinheiro S.V., Simoes e Silva A.C., Sampaio W.O., de Paula R.D., Mendes E.P., Bontempo E.D., Pesquero J.B., Walther T., Alenina N., Bader M., Bleich M., and Santos R.A. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 4 (2004) 490-496
19. Rabin M., Birnbaum D., Young D., Birchmeier C., Wigler M., and Ruddle F.H. Human ros1 and mas1 oncogenes located in regions of chromosome 6 associated with tumor-specific rearrangements. Oncogene Res 1 (1987) 169-178
20. Young D., O'Neill K., Jessell T., and Wigler M. Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain. Proc Natl Acad Sci U S A 85 (1988) 5339-5342
21. Zohn I.E., Symons M., Chrzanowska-Wodnicka M., Westwick J.K., and Der C.J. Mas oncogene signaling and transformation require the small GTP-binding protein Rac. Mol Cell Biol 18 (1998) 1225-1235
22. Jackson T.R., Blair A.C., Marshall J., Goedert M., and Hanley M.R. The mas oncogene encodes an angiotensin receptor. Nature 335 (1988) 437-440
23. Ambroz C., Clark A.J., and Catt K.J. The mas oncogene enhaces angiotensin-induced [Ca2+]i responses in cells with pre-existing angiotensin II receptors. Biochim Biophys Acta 1133 (1991) 107-111
24. Ardaillou R.J. Angiotensin II receptors. J Am Soc Nephrol 10 (1999) 30-39
25. Von Bohlen und Halbach O., Walther T., Bader M., and Albrecht D.J. Interaction between Mas and the angiotensin AT1 receptor in the amygdale. Neurophysiol 83 (2000) 2012-2021
26. Kostenis E., Milligan G., Christopoulos A., Sanchez-Ferrer C.F., Heringer-Walther S., Sexton P.M., Gembardt F., Kellett E., Martini L., Vanderheyden P., Schultheiss H.P., and Walther T. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111 (2005) 1806-1813
27. Canals M., Jenkins L., Kellett E., and Milligan G. Up-regulation of the angiotensin II type 1 receptor by the MAS proto-oncogene is due to constitutive activation of Gq/G11 by MAS. J Biol Chem 281 (2006) 16757-16767
28. Castro C.H., Santos R.A., Ferreira A.J., Bader M., Alenina N., and Almeida A.P. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 46 (2005) 937-942
29. Cverjic S., and Devi L.A. Dimerization of thr δ-opioid receptor: implication for a role in receptor internalization. J Biol Chem 272 (1997) 26959-26964
30. Scarselli M., Novi F., Schallmach E., Lin R., Baragli A., Colzi A., Griffon N., Corsini G.U., Sokoloff P., Levenson R., Vogel Z., and Maggio R. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 276 (2001) 30308-30314
31. Maggio R., Barbier P., Colelli A., Salvadori F., Demontis G., and Corsini G.U. G protein-linked receptors: pharmacological evidence for the formation of heterodimers. J Pharmacol Exp Ther 291 (1999) 251-257
32. Xu J., He J., Castleberry A.M., Balasubramanian S., Lau A.G., and Hall R.A. Heterodimerization of α2A- and β1-adrenergic receptors. J Biol Chem 278 (2003) 10770-10777
33. Ramsay D., Kellett E., McVey M., Rees S., and Milligan G. Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J 365 (2002) 429-440
34. AbdAlla S., Zaki E., Lother H., and Quitterer U. Involvement of the amino terminus of the B(2) receptor in agonist-induced receptor dimerization. J Biol Chem 274 (1999) 26079-26084
35. Monnot C., Bihoreau C., Conchon S., Curnow K.M., Corvol P., and Clauser E. Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. J Biol Chem 271 (1996) 1507-1513
36. AbdAlla S., Lother H., and Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407 (2000) 94-98
37. AbdAlla S., Lother H., Abdel-Tawab A.M., and Quitterer U. Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7 (2001) 1003-1009
38. AbdAlla S., Lother H., Abdel-Tawab A.M., and Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276 (2001) 39721-39726
39. Johansen T.E., Scholer M.S., Tolstoy S., and Schwartz T.W. Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukariotic expression vectors. FEBS Lett 267 (1990) 289-294
40. 3 (neurokinin B) receptors - identification of domains determining the binding specificity of tachykinin. J Biol Chem 268 (1993) 7893-7898
41. Kanashiro C.A., Paiva T.B., Paiva A.C., Prioste R.N., Aboulafia J., and Shimuta S.I. Angiotensin II tachyphylaxis in the guinea pig ileum and its prevention: a pharmacological and biochemical study. J Pharmacol Exp Ther 275 (1995) 1543-1550
42. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66 (2004) 1-7
43. Walther T., Balschun D., Voigt J.P., Fink H., Zuschrater W., Birchmeier C., Ganten D., and Bader M. Sustained long-term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem 273 (1998) 11867-11873
44. Le M.T., De Backer J.P., Hunyady L., Vanderheyden P.M., and Vauquelin G. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells. Eur J Pharmacol 513 (2005) 35-45
45. 2 receptors in cell growth. Trends Endocrinol Metab 10 (1999) 391-396
46. 2+. Biochem J 374 (2003) 281-296
47. Dixon B.S., Sharma R.V., Dickerson T., and Fortune J. Bradykinin and angiotensin II: activation of protein kinase C in arterial smooth muscle. Am J Physiol 266 (1994) C1406-C1420
48. Zhuo J., Dean R., Maric C., Aldred P.G., Harris P., Alcorn D., and Mendelsohn F.A. Localization and interactions of vasoactive peptide receptors in renomedullary interstitial cells of the kidney. Kidney Int 67 (1998) 22-28
49. Breitwieser G.E. G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ Res 94 (2004) 17-27
50. Wojcik J., Berg M.A., Esposito N., Geffner M.E., Sakati N., Reiter E.O., Dower S., Francke U., Postel-Vinay M.C., and Finidori J. Four contiguous amino acid substitutions, identified in patients with Laron syndrome, differently affect the binding affinity and intracellular trafficking of the growth hormone receptor. J Clin Endocrinol Metab 83 (1998) 4481-4489
51. Zerangue N., Schwappach B., Jan Y.N., and Jan L.Y. A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane KATP channels. Neuron 22 (1999) 537-548
52. Hermosilla R., Oueslati M., Donalies U., Schonenberger E., Krause E., Oksche A., Rosenthal W., and Schulein R. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic 5 (2004) 993-1005
53. Pahl H.L. Signal transduction from the endoplasmic reticulum to the cell nucleus. Physiol Rev 79 (1999) 683-701
54. Sommer T., and Wolf D.H. Endoplasmic reticulum degradation: reverse protein flow of no return. FASEB J 11 (1997) 1227-1233
55. Biederer T., Volkwein C., and Sommer T. Role of Cue1p in ubiquitination and degradation at the ER surface. Science 278 (1997) 1806-1809
56. Brodsky J.L., and McCracken A.A. ER protein quality control and proteasome-mediated protein degradation. Semin Cell Dev Biol 10 (1999) 507-513
57. Johnston J.A., Ward C.L., and Kopito R.R. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143 (1998) 1883-1898
58. Ohyama K., Yamano Y., Sano T., Nakagomi Y., Hamakubo T., Morishima I., and Inagami T. Disulfide bridges in extracellular domains of angiotensin II receptor type IA. Regul Pept 57 (1995) 141-147
59. Bulenger S., Marullo S., and Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 26 (2005) 131-137